Project Grant R03DK149525
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $623,607 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on August 1, 2026. The award funds research examining how impaired double-stranded DNA repair induces podocyte senescence and contributes to chronic kidney disease progression. The project integrates advanced genetic models, including podocyte-specific SETD1A knockout mice that develop focal segmental...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $488,592 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support a TL1 training program for predoctoral students, postdoctoral physician-scientists, and postdoctoral PhD scientists pursuing research-focused careers in adult and pediatric nephrologic, urologic, and hematologic health and disease. The program identifies and recruits...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $866,265 on May 13, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate non-canonical ephrin B2 receptor (EPHB2) signaling in acute kidney injury and its progression to chronic kidney disease. The research examines how EPHB2 and transforming growth factor beta signaling pathways contribute to kidney inflammation and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University a cooperative agreement for $195,437 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds the Connecticut Kidney, Urology, and Hematology Research Training (CKRT) Program, a TL1 training initiative that develops predoctoral and postdoctoral scientists for research careers in nephrology, urology, and classical hematology at...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $249,999 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate transcriptional dysregulation mechanisms in SF3B1-mutant myelodysplastic syndromes. The research focuses on defining the role of HTATSF1, a protein involved in both splicing and transcription, in transcriptional dysregulation in splicing-factor-mutant myelodysplastic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1.693 million on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop individualized immunosuppression regimens for kidney transplant recipients using machine learning and electronic health record data. The project addresses a clinical gap in immunosuppressive therapy optimization. Over 250,000 kidney transplant recipients depend...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New Mexico State University $146,070 on September 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund basic research into the role of fibroblast-derived lysyl oxidase in arteriovenous fistula maturation failure. The research will elucidate the molecular and cellular mechanisms by which lysyl oxidase upregulation increases the risk of arteriovenous fistula failure...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $872,273 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify modifiable process delays in deceased donor kidney allocation through process mining analysis. The project applies process mining methodology to discover actual kidney placement workflows from data logs at multiple organ procurement organizations (OPOs). The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $798,088 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate non-invasive predictive models for assessing acute tubular injury and interstitial fibrosis and tubular atrophy on kidney biopsy. The research leverages the Novel Approaches in the Investigation of Kidney Disease (NAIKID) study, an ongoing...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University (doing business as New York University School of Medicine) $1.674 million on September 24, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an empirically-based, optimal prehabilitation program for kidney transplant candidates on hemodialysis. The research addresses a significant clinical need: of more than 140,000 people waiting for kidney...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $126,000 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify vascular biomarkers and tissue signatures that predict cardiovascular risk in kidney transplant recipients. The project investigates whether early vascular biomarker trajectories and tissue expression patterns identify kidney transplant recipients at highest risk of cardiovascular disease events, including myocardial infarction, heart failure, stroke, or cardiovascular-related death. Aim 1 will conduct a nested matched case-control study (25 cases with cardiovascular events, 50 matched controls without events) measuring longitudinal plasma biomarkers of angiogenesis and endothelial injury and repair—including VEGF-A, VEGF-C, VEGF-D, VEGFR1, PLGF, BFGF, TIE-2, ANGPT-1, and ANGPT-2—across seven peri-transplant timepoints. The study will apply conditional logistic regression and elastic net modeling to derive a composite trajectory score and quantify predictive performance using optimism-corrected AUC, net reclassification index, and calibration metrics. Aim 2 will link biomarkers to tissue-level expression using spatial transcriptomics on archived six-month protocol biopsies from 25 cases and 25 matched controls to identify vascular injury and repair signatures that discriminate cases from controls. The period of performance runs from August 15, 2026, through July 31, 2028. Work is performed in New Haven, Connecticut.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $126.0k | 8/11/26 |